Also Read: Eli Lilly’s Obesity Drug Success Spurs Japanese Biotech’s Anti-Muscle-Wasting Combo Therapy Zepbound is an injectable prescription medicine that may help adults with obesity or some ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

NEW YORK (AP) — U.S. stocks are nudging lower on Tuesday, and oil prices are rising again. It’s a modest return to form for ...

U.S. stocks are falling and oil prices are rising again. The S&P 500 fell 0.8% Tuesday. The Dow Jones Industrial Average lost ...

Stocks sank under increasing pressure from crude oil prices, which climbed in their latest see-saw move. A barrel of ...

NEW YORK — (AP) — U.S. stocks slumped on Tuesday under the weight of another jump for the price of oil. It was a return to ...

Oil demand will peak at 105.6 million barrels per day (bpd) by 2029 and then fall slightly in 2030, a table in the Paris-based IEA’s annual report shows. At the same time, global production capacity ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...

June 20 (Reuters) - Eli Lilly (LLY.N), opens new tab said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in ...